Jove
Visualize
お問い合わせ
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. Covid-19 パンデミックの影響と,タイの入院結核患者の死亡率に対する病院の症例数と重症度の仲介的役割
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. Covid-19 パンデミックの影響と,タイの入院結核患者の死亡率に対する病院の症例数と重症度の仲介的役割

関連する実験動画

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

COVID-19 パンデミックの影響と,タイの入院結核患者の死亡率に対する病院の症例数と重症度の仲介的役割

Nyi Nyi Zayar1, Rassamee Chotipanvithayakul1, Alan Frederick Geater1

  • 1Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, 15 Kanjanavanich Road, Hat Yai, Songkhla, 90110, Thailand.

Global health research and policy
|August 26, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

COVID-19 パンデミックは結核 (TB) の症例数を減少させましたが,結核の病院での死亡率 (CFR) を増加させました. 結核による死亡の増加は 入院した重症者によるものであって 病院の質の低下によるものではない.

科学分野:

  • 公衆衛生
  • 感染症
  • 流行病学

背景:

  • 病院の症例数は,特にCOVID-19 パンデミックの間,ヘルスケアシステムのストレスとリソースの配分を反映しています.
  • 結核 (TB) などの他の病気に対するCOVID-19の影響を理解することは,公衆衛生にとって極めて重要です.
  • この研究では,COVID-19の病院負担が結核患者の結果にどのように影響したか調査しています.

研究 の 目的:

  • 結核 (TB) 死亡率 (CFR) に及ぼすCOVID-19の病院症例数の影響を評価する.
  • この影響が結核症例数や患者の重症度の変化によって引き起こされたかどうかを判断する.
  • パンデミック中に結核患者の病院でのケアの質を評価する.

主な方法:

  • タイの結核患者の入院データ (2017-2022) の遡及分析.
  • チャールソン併発症指数 (CCI) を用いて患者の重症度を定量化しました.
  • 割り切れたタイムシリーズ,レイグタイム,シリアルメディエーションの分析を使用した.

主要な成果:

  • COVID-19 期間中,月間結核病院の症例数は 12.9% 減少し,月間結核病院の CFR は 14.1% 増加した.
キーワード:
コロナウイルスチャールソン併発症指数病院の患者数死亡率重症度結核

さらに関連する動画

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.9K
A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
10:41

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

14.2K

関連する実験動画

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.9K
A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
10:41

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

14.2K

関連する概念動画

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

238
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
238
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

324
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
324
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

204
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
204
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

345
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
345
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

442
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
442
Pneumonia IV: Management01:28

Pneumonia IV: Management

447
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
447
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  • COVID-19症例数は結核症例数 (r=-0.60) と負の相関関係があり,結核CFR (r=0.74) と正の相関関係がある.
  • 結核の症例数と患者の重症度 (CCI) を調整したところ,COVID-19の症例数と結核病院のCFRとの間には直接的な関連性が見つかりませんでした.

    • 結論:

    • COVID-19 パンデミックの間,結核病院のCFRの増加は,主に入院している重症結核患者の割合が高いことによるものです.
    • これは,結核患者の病院での治療の質が必ずしも低下したとは言えません.
    • この発見は,パンデミックと既存の病気管理の複雑な相互作用を強調しています.